Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Non Operating Income (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Other Non Operating Income for 13 consecutive years, with -$72.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income fell 374.67% year-over-year to -$72.6 million, compared with a TTM value of -$62.4 million through Dec 2025, down 239.51%, and an annual FY2025 reading of -$62.4 million, down 239.51% over the prior year.
  • Other Non Operating Income was -$72.6 million for Q4 2025 at Karyopharm Therapeutics, down from -$7.4 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $26.4 million in Q4 2024 and bottomed at -$72.6 million in Q4 2025.
  • Average Other Non Operating Income over 5 years is -$946105.3, with a median of $16000.0 recorded in 2022.
  • The sharpest move saw Other Non Operating Income skyrocketed 47553.33% in 2024, then tumbled 374.67% in 2025.
  • Year by year, Other Non Operating Income stood at -$478000.0 in 2021, then skyrocketed by 97.28% to -$13000.0 in 2022, then surged by 784.62% to $89000.0 in 2023, then skyrocketed by 29583.15% to $26.4 million in 2024, then crashed by 374.67% to -$72.6 million in 2025.
  • Business Quant data shows Other Non Operating Income for KPTI at -$72.6 million in Q4 2025, -$7.4 million in Q3 2025, and -$2.2 million in Q2 2025.